Trials / Completed
CompletedNCT02593942
Remifentanil Infusion Alone During the Closure Period for Early Emergence Following Craniotomy
Effect of Remifentanil Infusion Alone During the Closure Period for Early Emergence and Hemodynamic Stability in Patients Undergoing Supratentorial Craniotomy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Yeditepe University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Total intravenous anaesthesia using propofol and remifentanil are routinely used drugs for this purpose. The hemodynamic stability and at the same time early emergency are the main goals following neurosurgery. However there is no standard for discontinuation time for manually controlled systems today. The investigators aimed to study the effect of remifentanil infusion alone for early emergence and hemodynamic stability during the closure period in patients undergoing supratentorial craniotomy.
Detailed description
Adult, American society of Anaesthesiologist score I-II, 80 patients who underwent elective supratentorial craniotomy for tumour resection were randomly assigned to group I or II. In group I; propofol was discontinued during the dural closure. After the propofol was discontinued, remifentanil dose was increased with the guidance of bispectral index spectrum and hemodynamic parameters. In group II; propofol discontinued before the end of the surgery. Time to awakening and extubation time, adverse events, total remifentanil and propofol consumptions and side effects were recorded. Heart rate and blood pressure were recorded during this period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remifentanil | 0.1-0.5 mcg/kg/min infusion |
| DRUG | Propofol | 75-200 mcg/kg/min infusion |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2015-11-02
- Last updated
- 2015-11-02
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT02593942. Inclusion in this directory is not an endorsement.